EIA Short-Term Energy Outlook: Despite short-term supply tightness due to disruptions, strong growth in global oil production is expected to continue to outpace consumption growth through 2027.

Goldman Sachs CEO Solomon: The macroeconomic situation is very favorable for risk assets.

Individual Stock News: 1. Country Garden (02007.HK): Yang Huiyan received a disciplinary decision from the Shanghai Stock Exchange for failing to disclose overdue debts in a timely manner. 2. SMIC (00981.HK) released its fourth-quarter results: The company achieved revenue of US$2.489 billion, a year-on-year increase of 12.8% and a quarter-on-quarter increase of 4.5%; profit attributable to owners of the company was US$173 million, a year-on-year increase of 60.7% and a quarter-on-quarter decrease of 9.9%. 3. WuXi Biologics (02269.HK): Expected net profit for the full year of 2025 to be RMB 4.91 billion, a year-on-year increase of 46.3%. 4. CITIC Securities (06030.HK): China Asset Management achieved operating revenue of RMB 9.626 billion and net profit of RMB 2.396 billion in 2025. 5. Zhaojin Mining (01818.HK): A sinkhole accident occurred in a blind shaft at the Shangzhuang section of the Canzhuang Gold Mine. The Canzhuang Gold Mine has an average annual gold production of approximately 1 ton and an average annual profit of approximately RMB 60 million. 6. PCCW (00008.HK) released its 2025 annual results: a loss attributable to shareholders of HK$253 million, narrowing by 16% year-on-year. 7. COFCO Jiajiakang (01610.HK) issued a profit warning: expecting an annual loss attributable to shareholders of approximately RMB 230 million to RMB 350 million, a shift from profit to loss year-on-year. 8. China Resources Pharmaceutical (03320.HK): Dong-E-E-Jiao plans to invest RMB 1.485 billion to build a health consumer goods industrial park. 9. Yue Yuen Group (00551.HK): January's net operating income was approximately US$705 million, a decrease of 12.5% year-on-year. 10. Pou Sheng International (03813.HK): January's consolidated net operating income was RMB 1.748 billion, a year-on-year decrease of 32.5%. 11. Hengrui Medicine (01276.HK): Its application for marketing authorization of trastuzumab for injection has been accepted and included in the priority review process.